Differential pricing

Published: 27-Aug-2001


BioPartners, the global biotechnology outsourcing company, and healthcare group Cambridge Laboratories, have signed an exclusive collaboration agreement for the UK. The agreement will cover a range of biopharmaceutical products from the BioPartners portfolio, including human growth hormone, alpha and beta interferon, erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor.

'BioPartners' product portfolio complements Cambridge Laboratories' existing product range very well,' said Mark Evans, ceo Cambridge Laboratories. 'Our goal is to serve the needs of healthcare specialists by providing them with niche hospital products which offer therapeutic benefit, particularly in the area of oncology and the CNS, and this agreement helps us to do exactly that.'

You may also like